Unknown

Dataset Information

0

AI/ML advances in non-small cell lung cancer biomarker discovery.


ABSTRACT: Lung cancer is the leading cause of cancer deaths among both men and women, representing approximately 25% of cancer fatalities each year. The treatment landscape for non-small cell lung cancer (NSCLC) is rapidly evolving due to the progress made in biomarker-driven targeted therapies. While advancements in targeted treatments have improved survival rates for NSCLC patients with actionable biomarkers, long-term survival remains low, with an overall 5-year relative survival rate below 20%. Artificial intelligence/machine learning (AI/ML) algorithms have shown promise in biomarker discovery, yet NSCLC-specific studies capturing the clinical challenges targeted and emerging patterns identified using AI/ML approaches are lacking. Here, we employed a text-mining approach and identified 215 studies that reported potential biomarkers of NSCLC using AI/ML algorithms. We catalogued these studies with respect to BEST (Biomarkers, EndpointS, and other Tools) biomarker sub-types and summarized emerging patterns and trends in AI/ML-driven NSCLC biomarker discovery. We anticipate that our comprehensive review will contribute to the current understanding of AI/ML advances in NSCLC biomarker research and provide an important catalogue that may facilitate clinical adoption of AI/ML-derived biomarkers.

SUBMITTER: Calıskan M 

PROVIDER: S-EPMC10750392 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature

altmetric image

Publications

AI/ML advances in non-small cell lung cancer biomarker discovery.

Çalışkan Minal M   Tazaki Koichi K  

Frontiers in oncology 20231211


Lung cancer is the leading cause of cancer deaths among both men and women, representing approximately 25% of cancer fatalities each year. The treatment landscape for non-small cell lung cancer (NSCLC) is rapidly evolving due to the progress made in biomarker-driven targeted therapies. While advancements in targeted treatments have improved survival rates for NSCLC patients with actionable biomarkers, long-term survival remains low, with an overall 5-year relative survival rate below 20%. Artifi  ...[more]

Similar Datasets

| S-EPMC5494096 | biostudies-literature
| S-EPMC8356077 | biostudies-literature
| S-ECPF-GEOD-37745 | biostudies-other
| S-EPMC6129543 | biostudies-literature
| S-EPMC4185902 | biostudies-literature
| S-EPMC10670348 | biostudies-literature
| S-EPMC2409840 | biostudies-other
| S-EPMC4129528 | biostudies-other
| S-EPMC10758313 | biostudies-literature
| S-EPMC6247002 | biostudies-literature